Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)
January 9, 2023 10:19 AM ESTUpdated 10:38 AM
Deals
Pharma

As­traZeneca bets up to $1.8B on Cin­Cor and its ex-Roche drug for hy­per­ten­sion

Nicole DeFeudis

Editor

Cin­Cor Phar­ma’s hy­per­ten­sion drug may have failed a Phase II study, but that doesn’t scare As­traZeneca.

The phar­ma gi­ant is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times